{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:28:10Z","timestamp":1786980490322,"version":"build-2736575974"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T00:00:00Z","timestamp":1719273600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T00:00:00Z","timestamp":1719273600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s10067-024-07031-1","type":"journal-article","created":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T05:01:54Z","timestamp":1719291714000},"page":"2521-2532","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Description of therapeutic strategies in severe systemic lupus erythematosus-associated immune thrombocytopenia: a retrospective cohort study of response and relapse"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7012-8419","authenticated-orcid":false,"given":"Erik","family":"Cim\u00e9-Ak\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1754-0500","authenticated-orcid":false,"given":"Ana","family":"Barrera-Vargas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0258-7397","authenticated-orcid":false,"given":"Roberta","family":"Demichelis-G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5068-1907","authenticated-orcid":false,"given":"Martha","family":"Ram\u00edrez-Alem\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4409-7548","authenticated-orcid":false,"given":"Marina","family":"Rull-Gabayet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,25]]},"reference":[{"key":"7031_CR1","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1097\/RHU.0000000000001083","volume":"26","author":"V Shobha","year":"2020","unstructured":"Shobha V, Sanil S, Roongta R (2020) Eltrombopag: Efficacy and Safety in Steroid Refractory Lupus-Associated Immune Thrombocytopenia. J Clin Rheumatol 26:274\u2013278. https:\/\/doi.org\/10.1097\/RHU.0000000000001083","journal-title":"J Clin Rheumatol"},{"key":"7031_CR2","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1002\/art.40930","volume":"71","author":"M Aringer","year":"2019","unstructured":"Aringer M, Costenbader K, Daikh D et al (2019) 2019 European League Against Rheumatism\/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis Rheumatol 71:1400\u20131412. https:\/\/doi.org\/10.1002\/art.40930","journal-title":"Arthritis Rheumatol"},{"key":"7031_CR3","doi-asserted-by":"publisher","first-page":"e2818","DOI":"10.1097\/MD.0000000000002818","volume":"95","author":"JH Jung","year":"2016","unstructured":"Jung JH, Soh MS, Ahn YH et al (2016) Thrombocytopenia in Systemic Lupus Erythematosus: Clinical Manifestations, Treatment, and Prognosis in 230 Patients. Medicine (Baltimore) 95:e2818. https:\/\/doi.org\/10.1097\/MD.0000000000002818","journal-title":"Medicine (Baltimore)"},{"key":"7031_CR4","doi-asserted-by":"publisher","first-page":"20","DOI":"10.31138\/mjr.28.1.20","volume":"28","author":"N Galanopoulos","year":"2017","unstructured":"Galanopoulos N, Christoforidou A, Bezirgiannidou Z (2017) Lupus thrombocytopenia: pathogenesis and therapeutic implications. Mediterr J Rheumatol 28:20\u201326. https:\/\/doi.org\/10.31138\/mjr.28.1.20","journal-title":"Mediterr J Rheumatol"},{"key":"7031_CR5","doi-asserted-by":"publisher","first-page":"e15016","DOI":"10.1111\/1756-185X.15016","volume":"27","author":"SS Mohamed","year":"2024","unstructured":"Mohamed SS, Gamal SM, Mokbel A (2024) Thrombocytopenia and disease outcomes in a cohort of patients with systemic lupus erythematosus. A post hoc analysis of the COMOSLE-EGYPT study. Int J Rheum Dis 27:e15016. https:\/\/doi.org\/10.1111\/1756-185X.15016","journal-title":"Int J Rheum Dis"},{"key":"7031_CR6","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1007\/s00296-020-04668-4","volume":"40","author":"O Ilizaliturri-Guerra","year":"2020","unstructured":"Ilizaliturri-Guerra O, Uriarte-Botello R, Pineda-Sic R\u00c1 et al (2020) Low-dose rituximab therapy in steroid-refractory thrombocytopenia due to systemic lupus erythematosus. Rheumatol Int 40:1717\u20131724. https:\/\/doi.org\/10.1007\/s00296-020-04668-4","journal-title":"Rheumatol Int"},{"key":"7031_CR7","doi-asserted-by":"publisher","first-page":"883","DOI":"10.3346\/jkms.2005.20.5.883","volume":"20","author":"HK Chang","year":"2005","unstructured":"Chang HK (2005) Successful treatment of refractory thrombocytopenia with mycophenolate mofetil in a patient with systemic lupus erythematosus. J Korean Med Sci 20:883\u2013885. https:\/\/doi.org\/10.3346\/jkms.2005.20.5.883","journal-title":"J Korean Med Sci"},{"key":"7031_CR8","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1080\/25785826.2019.1696644","volume":"42","author":"K Abe","year":"2019","unstructured":"Abe K, Ishikawa Y, Ishikawa J et al (2019) Successful treatment of a patient with refractory immune thrombocytopenic purpura in systemic lupus erythematosus with rituximab. Immunol Med 42:185\u2013188. https:\/\/doi.org\/10.1080\/25785826.2019.1696644","journal-title":"Immunol Med"},{"key":"7031_CR9","doi-asserted-by":"publisher","first-page":"444","DOI":"10.31138\/mjr.33.4.444","volume":"33","author":"F Uluta\u015f","year":"2022","unstructured":"Uluta\u015f F, \u00d6k ZD, U\u011fur K et al (2022) Successful Treatment of Systemic Lupus Erythematosus-Associated Thrombocytopenia with Eltrombopag: A Report of Two Cases and Literature Review. Mediterr J Rheumatol 33:444\u2013448. https:\/\/doi.org\/10.31138\/mjr.33.4.444","journal-title":"Mediterr J Rheumatol"},{"key":"7031_CR10","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1191\/0961203303lu417cr","volume":"12","author":"S Vasoo","year":"2003","unstructured":"Vasoo S, Thumboo J, Fong KY (2003) Refractory immune thrombocytopenia in systemic lupus erythematosus: response to mycophenolate mofetil. Lupus 12:630\u2013632. https:\/\/doi.org\/10.1191\/0961203303lu417cr","journal-title":"Lupus"},{"key":"7031_CR11","doi-asserted-by":"publisher","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","volume":"3","author":"C Neunert","year":"2019","unstructured":"Neunert C, Terrell DR, Arnold DM et al (2019) American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv 3:3829\u20133866. https:\/\/doi.org\/10.1182\/bloodadvances.2019000966","journal-title":"Blood Adv"},{"key":"7031_CR12","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1080\/10245332.2018.1461317","volume":"23","author":"C Chen","year":"2018","unstructured":"Chen C, Song J, Wang Q et al (2018) Mean platelet volume at baseline and immune thrombocytopenia relapse in Chinese newly-diagnosed patients: a retrospective cohort study. Hematology 23:646\u2013652. https:\/\/doi.org\/10.1080\/10245332.2018.1461317","journal-title":"Hematology"},{"key":"7031_CR13","first-page":"75","volume":"29","author":"C Arnal","year":"2002","unstructured":"Arnal C, Piette JC, L\u00e9one J et al (2002) Treatment of severe immune thrombocytopenia associated with systemic lupus erythematosus: 59 cases. J Rheumatol 29:75\u201383","journal-title":"J Rheumatol"},{"key":"7031_CR14","doi-asserted-by":"publisher","first-page":"204062232311606","DOI":"10.1177\/20406223231160688","volume":"14","author":"HJ Li","year":"2023","unstructured":"Li HJ, Zheng YQ, Chen L (2023) Risk factors of significant relapse and appropriate maintenance therapy strategy in SLE-associated immune thrombocytopenia. Ther Adv Chronic Dis 14:20406223231160690. https:\/\/doi.org\/10.1177\/20406223231160688","journal-title":"Ther Adv Chronic Dis"},{"key":"7031_CR15","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41584-020-0371-y","volume":"16","author":"RS Hardy","year":"2020","unstructured":"Hardy RS, Raza K, Cooper MS (2020) Therapeutic glucocorticoids: mechanisms of actions in rheumatic diseases. Nat Rev Rheumatol 16:133\u2013144. https:\/\/doi.org\/10.1038\/s41584-020-0371-y","journal-title":"Nat Rev Rheumatol"},{"key":"7031_CR16","doi-asserted-by":"publisher","first-page":"e22938","DOI":"10.7759\/cureus.22938","volume":"14","author":"JC Santacruz","year":"2022","unstructured":"Santacruz JC, Mantilla MJ, Rueda I et al (2022) A Practical Perspective of the Hematologic Manifestations of Systemic Lupus Erythematosus. Cureus 14:e22938. https:\/\/doi.org\/10.7759\/cureus.22938","journal-title":"Cureus"},{"key":"7031_CR17","doi-asserted-by":"publisher","first-page":"674","DOI":"10.7326\/0003-4819-112-9-674","volume":"112","author":"DT Boumpas","year":"1990","unstructured":"Boumpas DT, Barez S, Klippel JH (1990) Intermittent cyclophosphamide for the treatment of autoimmune thrombocytopenia in systemic lupus erythematosus. Ann Intern Med 112:674\u2013677. https:\/\/doi.org\/10.7326\/0003-4819-112-9-674","journal-title":"Ann Intern Med"},{"key":"7031_CR18","doi-asserted-by":"publisher","first-page":"472","DOI":"10.3346\/jkms.2013.28.3.472","volume":"28","author":"HJ Park","year":"2013","unstructured":"Park HJ, Kang MI, Kang Y et al (2013) Two cases of refractory thrombocytopenia in systemic lupus erythematosus that responded to intravenous low-dose cyclophosphamide. J Korean Med Sci 28:472\u2013475. https:\/\/doi.org\/10.3346\/jkms.2013.28.3.472","journal-title":"J Korean Med Sci"},{"key":"7031_CR19","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1055\/s-0039-1684032","volume":"39","author":"MP Lambert","year":"2019","unstructured":"Lambert MP (2019) Immunomodulatory Second-Line Therapies for Immune Thrombocytopenia. Hamostaseologie 39:266\u2013271. https:\/\/doi.org\/10.1055\/s-0039-1684032","journal-title":"Hamostaseologie"},{"key":"7031_CR20","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1177\/0961203311411349","volume":"20","author":"RK Gupta","year":"2011","unstructured":"Gupta RK, Ezeonyeji AN, Thomas AS et al (2011) A case of pure red cell aplasia and immune thrombocytopenia complicating systemic lupus erythematosus: response to rituximab and cyclophosphamide. Lupus 20:1547\u20131550. https:\/\/doi.org\/10.1177\/0961203311411349","journal-title":"Lupus"},{"key":"7031_CR21","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jaut.2016.07.001","volume":"74","author":"A Velo-Garc\u00eda","year":"2016","unstructured":"Velo-Garc\u00eda A, Castro SG, Isenberg DA (2016) The diagnosis and management of the haematologic manifestations of lupus. J Autoimmun 74:139\u2013160. https:\/\/doi.org\/10.1016\/j.jaut.2016.07.001","journal-title":"J Autoimmun"},{"key":"7031_CR22","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.reuma.2018.03.005","volume":"16","author":"L Gupta","year":"2020","unstructured":"Gupta L, Gupta V, Pani KC et al (2020) Successful use of azathioprine in glucocorticoid refractory immune amegakaryocytic thrombocytopenia of lupus. Reumatol Clin (Engl Ed) 16:249\u2013250. https:\/\/doi.org\/10.1016\/j.reuma.2018.03.005","journal-title":"Reumatol Clin (Engl Ed)"},{"key":"7031_CR23","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1002\/ajh.24999","volume":"93","author":"A Serris","year":"2018","unstructured":"Serris A, Amoura Z, Canou\u00ef-Poitrine F et al (2018) Efficacy and safety of rituximab for systemic lupus erythematosus-associated immune cytopenias: A multicenter retrospective cohort study of 71 adults. Am J Hematol 93:424\u2013429. https:\/\/doi.org\/10.1002\/ajh.24999","journal-title":"Am J Hematol"},{"key":"7031_CR24","doi-asserted-by":"publisher","first-page":"204062232110486","DOI":"10.1177\/20406223211048643","volume":"12","author":"S Zhang","year":"2021","unstructured":"Zhang S, Jiang N, Wang L et al (2021) A modified regimen of low-dose rituximab therapy for patients with refractory immune thrombocytopenia associated with systemic lupus erythematosus. Ther Adv Chronic Dis 12:20406223211048644. https:\/\/doi.org\/10.1177\/20406223211048643","journal-title":"Ther Adv Chronic Dis"},{"key":"7031_CR25","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1093\/rheumatology\/keab925","volume":"61","author":"M Roussotte","year":"2022","unstructured":"Roussotte M, Gerfaud-Valentin M, Hot A et al (2022) Immune thrombocytopenia with clinical significance in systemic lupus erythematosus: a retrospective cohort study of 90 patients. Rheumatology (Oxford) 61:3627\u20133639. https:\/\/doi.org\/10.1093\/rheumatology\/keab925","journal-title":"Rheumatology (Oxford)"},{"key":"7031_CR26","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.1007\/s10067-020-05152-x","volume":"39","author":"F Sun","year":"2020","unstructured":"Sun F, Chen J, Wu W et al (2020) Rituximab or cyclosporin in refractory immune thrombocytopenia secondary to connective tissue diseases: a real-world observational retrospective study. Clin Rheumatol 39:3099\u20133104. https:\/\/doi.org\/10.1007\/s10067-020-05152-x","journal-title":"Clin Rheumatol"},{"key":"7031_CR27","doi-asserted-by":"publisher","first-page":"102887","DOI":"10.1016\/j.jaut.2022.102887","volume":"132","author":"Y Jiang","year":"2022","unstructured":"Jiang Y, Cheng Y, Ma S et al (2022) Systemic lupus erythematosus-complicating immune thrombocytopenia: From pathogenesis to treatment. J Autoimmun 132:102887. https:\/\/doi.org\/10.1016\/j.jaut.2022.102887","journal-title":"J Autoimmun"},{"key":"7031_CR28","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1056\/NEJMoa2100596","volume":"385","author":"CA Bradbury","year":"2021","unstructured":"Bradbury CA, Pell J, Hill Q et al (2021) Mycophenolate Mofetil for First-Line Treatment of Immune Thrombocytopenia. N Engl J Med 385:885\u2013895. https:\/\/doi.org\/10.1056\/NEJMoa2100596","journal-title":"N Engl J Med"},{"key":"7031_CR29","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1177\/0961203313490239","volume":"22","author":"LM Blasco","year":"2013","unstructured":"Blasco LM (2013) Hydroxychloroquine alone for severe immune thrombocytopenic purpura associated with systemic lupus erythematosus. Lupus 22:752\u2013753. https:\/\/doi.org\/10.1177\/0961203313490239","journal-title":"Lupus"},{"key":"7031_CR30","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1002\/ajh.23609","volume":"89","author":"M Khellaf","year":"2014","unstructured":"Khellaf M, Chabrol A, Mahevas M et al (2014) Hydroxychloroquine is a good second-line treatment for adults with immune thrombocytopenia and positive antinuclear antibodies. Am J Hematol 89:194\u2013198. https:\/\/doi.org\/10.1002\/ajh.23609","journal-title":"Am J Hematol"},{"key":"7031_CR31","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1111\/j.1365-2141.1990.tb02569.x","volume":"74","author":"I Quiquandon","year":"1990","unstructured":"Quiquandon I, Fenaux P, Caulier MT et al (1990) Re-evaluation of the role of azathioprine in the treatment of adult chronic idiopathic thrombocytopenic purpura: a report on 53 cases. Br J Haematol 74:223\u2013228. https:\/\/doi.org\/10.1111\/j.1365-2141.1990.tb02569.x","journal-title":"Br J Haematol"},{"key":"7031_CR32","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1007\/s00277-002-0488-x","volume":"81","author":"GE Pamuk","year":"2002","unstructured":"Pamuk GE, Pamuk ON, Ba\u015flar Z et al (2002) Overview of 321 patients with idiopathic thrombocytopenic purpura. Retrospective analysis of the clinical features and response to therapy. Ann Hematol 81:436\u2013440. https:\/\/doi.org\/10.1007\/s00277-002-0488-x","journal-title":"Ann Hematol"},{"key":"7031_CR33","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13075-024-03305-w","volume":"26","author":"J Li","year":"2024","unstructured":"Li J, Peng L, Wu L et al (2024) Antiphospholipid antibodies as potential predictors of disease severity and poor prognosis in systemic lupus erythematosus-associated thrombocytopenia: results from a real-world CSTAR cohort study. Arthritis Res Ther 26:67. https:\/\/doi.org\/10.1186\/s13075-024-03305-w","journal-title":"Arthritis Res Ther"},{"key":"7031_CR34","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.semarthrit.2015.11.003","volume":"45","author":"LA Gonz\u00e1lez-Naranjo","year":"2016","unstructured":"Gonz\u00e1lez-Naranjo LA, Betancur OM, Alarc\u00f3n GS et al (2016) Features associated with hematologic abnormalities and their impact in patients with systemic lupus erythematosus: Data from a multiethnic Latin American cohort. Semin Arthritis Rheum 45:675\u2013683. https:\/\/doi.org\/10.1016\/j.semarthrit.2015.11.003","journal-title":"Semin Arthritis Rheum"},{"key":"7031_CR35","doi-asserted-by":"publisher","first-page":"e000677","DOI":"10.1136\/lupus-2022-000677","volume":"9","author":"K Su","year":"2022","unstructured":"Su K, Cheng H, Jia Z et al (2022) Predictors of refractory risk in systemic lupus erythematosus-related thrombocytopenia: a dual-centre retrospective study. Lupus Sci Med 9:e000677. https:\/\/doi.org\/10.1136\/lupus-2022-000677","journal-title":"Lupus Sci Med"},{"key":"7031_CR36","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1007\/s10067-010-1479-2","volume":"29","author":"DS Domiciano","year":"2010","unstructured":"Domiciano DS, Shinjo SK (2010) Autoimmune hemolytic anemia in systemic lupus erythematosus: association with thrombocytopenia. Clin Rheumatol 29:1427\u20131431. https:\/\/doi.org\/10.1007\/s10067-010-1479-2","journal-title":"Clin Rheumatol"},{"key":"7031_CR37","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1080\/09537104.2016.1214253","volume":"28","author":"SM Abdel Galil","year":"2017","unstructured":"Abdel Galil SM, Edrees AM, Ajeeb AK et al (2017) Prognostic significance of platelet count in SLE patients. Platelets 28:203\u2013207. https:\/\/doi.org\/10.1080\/09537104.2016.1214253","journal-title":"Platelets"},{"key":"7031_CR38","doi-asserted-by":"publisher","first-page":"e0225516","DOI":"10.1371\/journal.pone.0225516","volume":"14","author":"N Jiang","year":"2019","unstructured":"Jiang N, Li M, Zhang M et al (2019) Chinese SLE Treatment and Research group (CSTAR) registry: Clinical significance of thrombocytopenia in Chinese patients with systemic lupus erythematosus. PLoS One 14:e0225516. https:\/\/doi.org\/10.1371\/journal.pone.0225516","journal-title":"PLoS One"},{"key":"7031_CR39","doi-asserted-by":"publisher","first-page":"981375","DOI":"10.3389\/fimmu.2022.981375","volume":"13","author":"Y Yoshida","year":"2022","unstructured":"Yoshida Y, Nishi H (2022) The role of the complement system in kidney glomerular capillary thrombosis. Front Immunol 13:981375. https:\/\/doi.org\/10.3389\/fimmu.2022.981375","journal-title":"Front Immunol"},{"key":"7031_CR40","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1160\/TH13-02-0102","volume":"110","author":"A Verschoor","year":"2013","unstructured":"Verschoor A, Langer HF (2013) Crosstalk between platelets and the complement system in immune protection and disease. Thromb Haemost 110:910\u2013919. https:\/\/doi.org\/10.1160\/TH13-02-0102","journal-title":"Thromb Haemost"},{"key":"7031_CR41","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1007\/s10067-023-06641-5","volume":"42","author":"V Shobha","year":"2023","unstructured":"Shobha V, Rajasekhar L, Bhat V (2023) Severe thrombocytopenia is associated with high mortality in systemic lupus erythematosus-analysis from Indian SLE Inception cohort for Research (INSPIRE). Clin Rheumatol 42:2279\u20132285. https:\/\/doi.org\/10.1007\/s10067-023-06641-5","journal-title":"Clin Rheumatol"},{"key":"7031_CR42","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1007\/s00296-023-05469-1","volume":"43","author":"M Arrucha-Cozaya","year":"2023","unstructured":"Arrucha-Cozaya M, Zamora-Z\u00fa\u00f1iga NC, Miranda-Hern\u00e1ndez D (2023) In-hospital mortality and associated factors in patients with systemic lupus erythematosus: analysis over more than 11 years in a reference hospital center. Rheumatol Int 43:2221\u20132231. https:\/\/doi.org\/10.1007\/s00296-023-05469-1","journal-title":"Rheumatol Int"},{"key":"7031_CR43","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1097\/01.sla.0000133182.92780.9c","volume":"240","author":"YN You","year":"2004","unstructured":"You YN, Tefferi A, Nagorney DM (2004) Outcome of splenectomy for thrombocytopenia associated with systemic lupus erythematosus. Ann Surg 240:286\u2013292. https:\/\/doi.org\/10.1097\/01.sla.0000133182.92780.9c","journal-title":"Ann Surg"},{"key":"7031_CR44","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s00296-009-1207-x","volume":"31","author":"R Li","year":"2011","unstructured":"Li R, Liu G, Wang K et al (2011) Splenectomy for thrombocytopenia associated with systemic lupus erythematosus in 11 Chinese patients. Rheumatol Int 31:9\u201315. https:\/\/doi.org\/10.1007\/s00296-009-1207-x","journal-title":"Rheumatol Int"},{"key":"7031_CR45","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1177\/09612033241241576","volume":"33","author":"Q Wu","year":"2024","unstructured":"Wu Q, Zhao MX, Huang XS et al (2024) The use of belimumab on patients with both systemic lupus erythematosus and immune thrombocytopenia: A retrospective cohort study. Lupus 33:608\u2013614. https:\/\/doi.org\/10.1177\/09612033241241576","journal-title":"Lupus"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-024-07031-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-024-07031-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-024-07031-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T08:17:37Z","timestamp":1721809057000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-024-07031-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,25]]},"references-count":45,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["7031"],"URL":"https:\/\/doi.org\/10.1007\/s10067-024-07031-1","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,25]]},"assertion":[{"value":"7 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study involved human subjects and was approved by the Instituto Nacional de Ciencias M\u00e9dicas y Nutrici\u00f3n Salvador Zubir\u00e1n Research and Ethics Committee with registration number IRE-4027\u201322-22\u20131. This is a retrospective cohort study and the information analyzed comes from a historical data registry, so the requirement for written informed consent was waived by the Committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare that there is no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}